Motif Bio Announces Filing of U.S. Shelf Registration

Pharmaceutical Investing

Motif Bio® (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has filed a “universal” shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission. As quoted in the press release: This shelf registration statement has been filed with the SEC, but has not yet become …

This shelf registration statement has been filed with the SEC, but has not yet become effective. Any offers, solicitations of offers to buy, or sales of these securities will only be made once the shelf registration statement has been declared effective by the SEC, including any prospectuses and prospectus supplements.

Click here to read the full press release.

clinical-stage biopharmaceutical clinical-stage biopharmaceutical company sec u.s. securities and exchange commission Pharmaceutical Investing